BACKGROUND: Considerable controversy exists regarding the choice of balloon used for performing angioplasty as treatment of cerebral vasospasm associated with subarachnoid hemorrhage. OBJECTIVE: To determine the impact of compliant and noncompliant balloons on angiographic and clinical outcomes among patients with subarachnoid hemorrhagerelated cerebral vasospasm. METHODS: Consecutive patients with cerebral vasospasm who underwent balloon angioplasty were included. Patient characteristics, rate of angiographic recurrence, and occurrence of cerebral infarcts in the affected vessel distribution were compared between arteries treated using different balloons. RESULTS: A total of 30 patients underwent a first-time angioplasty using compliant (n = 34) or noncompliant (n = 51) balloons. At admission, patients were classified Hunt and Hess grade I to III (n = 20) and Hunt and Hess grade IV to V (n = 10). Fisher grades in patients were I (n = 1), II (n = 3), III (n = 20), and IV (n = 6). No significant differences in the rate of angiographic recurrence (32% vs 53%; P = .14), need for repeat angioplasty (21% vs 20%; P = .97), and occurrence of cerebral infarcts in the affected arterial distribution (21% vs 10% P = .39) were observed with compliant and noncompliant balloons, respectively. Independent of the balloon type, a significant reduction in the need for repeat angioplasty was observed when the initial angioplasty resulted in a normal or supranormal diameter compared with a subnormal diameter (63.5% vs 36.5%; P = .01). CONCLUSION: No clear difference was observed between compliant and noncompliant balloons for therapeutic angioplasty in preventing angiographic recurrence or the need for repeat angioplasty in patients with subarachnoid hemorrhage-related cerebral vasospasm. An immediate normal or supranormal vessel diameter after the first-time angioplasty resulted in a significant reduction in the need for repeat angioplasty.
At present, the angiographic and clinical benefit of balloon angioplasty in the presence of symptomatic or angiographic vasospasm from aneurysmal SAH is well reported in several caseseries. [11] [12] [13] [14] [15] The American Heart Association practice guidelines state that vasodilators and balloon angioplasty are considered class IIb/Level of Evidence B 16 for treatment of cerebral vasospasm associated with SAH.
The constant development and improvement in balloon technology for intracranial use have provided a variety of options. The balloons are commonly classified according to the volume change incurred by subsequent increasing pressure (compliance) and are divided into compliant and noncompliant balloons. Compliant balloons are available in limited diameters and lengths, and noncompliant balloons are available in a larger selection of both lengths and diameters. The radial force exerted by a noncompliant balloon is higher than that of a compliant balloon, and therefore overdilation may lead to dissections and rupture. However, the final inflation diameter is well defined as a function of insufflation pressure allowing appropriate matching to diameter of the target artery. The strong radial force and balloon insufflation diameter accuracy are the key features for clinical application in intracranial atherosclerotic lesions, 17 but SAH-related vasospasm is different from atherosclerotic lesions. Vasospasm in SAH involves entire arterial segments rather than focal segments or stenosis seen in atherosclerotic lesions; therefore, a high radial force is not an essential requirement in vasospasm treatment. Although compliant balloons have a lower radial force, arterial injury and rupture is always possible because of variations in the final inflation diameter. However, a larger dilation with uniform radial force across relatively large segments may be possible with compliant balloons with lower risk of arterial injury, resulting in more sustainable results.
There is considerable controversy regarding the best balloon (compliant vs noncompliant) for the treatment of cerebral vasospasm. Because of the different balloon properties and balloon preference by operators, we performed an analysis to determine the impact of balloon characteristics on angiographic and clinical outcomes among patients with SAH-related cerebral vasospasm. We hypothesize that the characteristics of balloons used for the initial therapeutic angioplasty will result in differential rates of vasospasm recurrence and need for second treatment with subsequent reduction in cerebral infarction in the affected arterial distribution.
PATIENTS AND METHODS

Patients
A retrospective analysis of consecutive patients with SAH-related cerebral vasospasm was performed. The patients were identified from 2 university-affiliated medical centers from a prospective procedure log that included pertinent data for all neuroendovascular procedures performed from December 2006 to November 2009. The patients who underwent intracranial balloon angioplasty for SAH-related vasospasm were selected for additional data collection and analysis. The patient demographic and clinical characteristics, initial Hunt and Hess grade, 18, 19 Fisher grade, 20 and time interval (in days) between SAH onset and initial angioplasty were recorded.
Medical Management of Vasospasm From SAH
All patients with SAH were treated with oral nimodipine (60 mg) every 4 hours. An effort to ensure that a central venous pressure was maintained between 3 and 5 mm Hg (normovolemia) was made. When symptomatic vasospasm was suspected based on clinical findings and concomitant transcranial Doppler ultrasound demonstrated vasospasm, 21 the central venous pressure goal was increased to 8 to 12 mm Hg with concurrent augmentation of systemic systolic blood pressure to a target of 160 to 180 mm Hg followed by an emergent cerebral angiogram. The time from treatment decision and treatment initiation was not recorded. An established acute stroke intervention protocol was used at both institutions to ensure prompt treatment of cerebral vasospasm. Methods and results of this acute stroke response protocol are available in a previous publication. 22 Our goal was to initiate intervention within 2 hours of symptom onset, but the ascertainment was sometimes confounded in patients in whom a clear onset was not identifiable.
Technical Description of Endovascular Vasospasm Treatment
Patients were brought to the neuroangiography suite and a 6-French introducer sheath was placed in the common femoral artery. Through the introducer sheath, a 6-French guide catheter was advanced into the internal carotid artery or vertebral artery. The decisions regarding the choice and size of balloon catheter and whether to infuse vasodilators through a microcatheter were made by the treating physician on a caseby-case basis. A total of 4 primary operators performed balloon angioplasty; 2 exclusively used noncompliant balloons and the remaining 2 primarily used compliant balloons. The cases were randomly distributed among treating physicians based on call schedule. When angioplasty was planned, intravenous heparin was administered to achieve a target activate clotting time greater than 250 seconds. Subsequently, either a compliant balloon (Hyperglide or Hyperform; ev3, Inc., Irvine, California) or a noncompliant balloon (Maverick or Gateway, Boston Scientific, Freemont, California; Sprinter, Medtronic, Minneapolis, Minnesota; Voyager, Abbott Vascular, Abbott Park, Illinois) catheter was advanced into the arterial segment of interest. Angioplasty was performed in the presence of moderate to severe and severe angiographic vasospasm involving the intracranial internal carotid artery, middle cerebral artery M1 segment, anterior cerebral artery A1 segment, intracranial vertebral artery, basilar artery, and, infrequently, in the posterior cerebral artery P1 segment and M2 segment. The noncompliant balloon nominal diameter was chosen based on the original diameter of the vessel (before vasospasm) when available; if such data were not available, the measurements from the contralateral vessel were used. The balloon was inflated to nominal pressure at a rate of 2 to 4 atm per minute using a manual insufflation device; if multiple angioplasties were required, it was deflated at a rate of 3 to 4 atm/min and repositioned in a more proximal segment, and the balloon was inflated again. In situations in which the diameter of the proximal vessel was considered larger than the nominal diameter of the balloon, this was inflated to a supranominal pressure but below rated burst pressure or exchanged for a larger diameter balloon. The compliant balloon often used was the 4 3 10-mm Hyperglide or 4 3 7-mm Hyperform balloon, and when serial angioplasties were planned, it was performed in similar fashion (from a distal vessel to a proximal vessel). These balloons were slowly inflated using a 1-mL syringe following closely the balloon morphology under fluoroscopy and syringe tactile feedback during inflation. When vasodilators were infused as supplementary treatment, a microcatheter ranging in diameter from 1.4 to 2.3 French was advanced over a 0.014 microwire into the vessel of interest, and at the primary operator's discretion, verapamil or nicardipine was infused. The dose and concentration of administration are described in a previous publication. 23 
Outcomes
One of the investigators (J.T.M.) reviewed all the computed tomography and angiographic images without knowledge of the characteristics of the balloon used. We recorded any new cerebral infarction demonstrable on computed tomography within the vascular territory of where balloon angioplasty was performed, ascertained after a minimum 24-hour interval between the procedure and scan acquisition to ensure adequate ascertainment. Vessels with vasospasm were classified using an already acceptable method of quantitating severity of angiographic vasospasm 24 into mild (0-33%), moderate (34%-66%), and severe (67%-100%) using as reference the initial angiogram, if available. The immediate postangioplasty result was adjudicated similarly but with 2 additional grades. If the caliber achieved after the angioplasty was considered to be the normal original diameter, this was classified as normal diameter, and if the caliber was greater than the original normal diameter, this was classified as supranormal. A normal or supranormal diameter was considered an outcome variable. The need for angioplasty retreatment (repeat angioplasty in a previously treated vessel segment) was based on visualization of moderate to severe or severe angiographic vasospasm during follow-up cerebral angiograms. Recurrent angiographic vasospasm (vasospasm recurrence) was defined as moderate, moderate to severe, and severe vasospasm of an arterial segment that was previously treated with balloon angioplasty.
Statistical Analysis
Patient demographic and clinical characteristics were compared between arteries initially treated using compliant and noncompliant balloons using the Fisher exact test for categorical variables and the t test for continuous variables. The arteries were classified based on the initial procedure. The rate of angiographic recurrence and occurrence of cerebral infarcts in the affected vessel distribution where a previous angioplasty was performed were compared between arteries treated with compliant and noncompliant balloons using a generalized estimating equation to obtain adjusted odds ratios estimates and 95% confidence intervals. The nested design of the data was incorporated in the analysis (arteries within patients). The distribution of clinical severity was different between patients treated with compliant and noncompliant balloons (patients with a poor grade were only treated with noncompliant balloons) by chance; therefore, this variable was not included as a covariate in the multivariable model. Instead, a subset analysis was performed restricted to only patients with Fisher grades 3 and 4.
RESULTS
A total of 125 patients with SAH were admitted during the study duration. Of these, 30 patients underwent treatment with balloon angioplasty for treatment of angiographic vasospasm. The mean age 6 standard deviation of the 30 patients was 48 6 12 years, 70% were women (n = 21), and 73% were white (n = 22). A total of 20 and 10 patients were classified as good grade (Hunt and Hess grades I-III) and poor grade (Hunt and Hess grades IV-V) at admission, respectively. Fisher grades were I (n = 1), II (n = 3), III (n = 20), and IV (n = 6). The underlying etiologies for SAH were as follows: aneurysmal rupture (n = 28), postsurgical SAH (n = 1), and intracerebral hemorrhage with SAH extension of undetermined etiology (n = 1).
A first-time angioplasty was performed in 85 arteries. Compliant balloons were used in 34 arteries and noncompliant balloons in 51 arteries. A repeat angioplasty (first recurrence) was performed in 17 arteries (12 patients), 9 angioplasty procedures were performed using compliant balloons, and 8 procedures were performed using noncompliant balloons. Between the first-time angioplasty and first repeat angioplasty, 3 arteries crossed over to undergo angioplasty with noncompliant balloon and 5 arteries crossed over to compliant balloon angioplasty. A third angioplasty (second recurrence) was required in 3 arteries that were treated using noncompliant balloons in 3 patients. Before the third angioplasty, noncompliant balloons were used in 2 arteries and a compliant balloon in 1 artery (Figure) .
The patient demographic and clinical characteristics, time to treatment, number of arteries treated during the first-time angioplasty procedure, and arteries treated did not differ between procedures using compliant and noncompliant balloons ( Table 1) . The proportion of patients according to initial Fisher and Hunt and Hess grades was different between patients whose vessels were treated with compliant and noncompliant balloons (P = .002 for Fisher, and P = .0001 for Hunt and Hess).
The rates of first-time angioplasty using compliant balloons and noncompliant balloons were similar among vessels in patients with Hunt and Hess grades III and IV (34 vessels vs 33 vessels). In patients with Hunt and Hess grades I to II, the rate of firsttime angioplasty using compliant balloons and noncompliant balloons was asymmetrical (0 vessels vs 18 vessels). This difference in choice of balloons during first-time angioplasty was attributable to chance in the absence of a stratified randomized design.
During follow-up angiograms after the first-time angioplasty, neither compliant nor noncompliant balloon was superior in reducing angiographic vasospasm recurrence and the need for repeat therapeutic angioplasty. The results were similar when all vessels treated (first-time angioplasty [n = 85] vessels and repeat angioplasty [n = 20]) were pooled in the analysis (Table 2) . Similar results were obtained in all strata defined by initial Fisher grade (Table 3) .
A total of 12 arterial distribution infarctions despite balloon angioplasty were visualized on serial computed tomography scans. These infarcts occurred in 7 arterial territories (5 patients) that were initially treated using compliant balloons and in 5 territories (3 patients) that were initially treated using noncompliant balloons. This difference in the rate of new cerebral infarction was not significant (odds ratio: 1.7, 9% confidence interval: 0.51-5.8, P = .39) between the 2 groups. There were no arterial ruptures or arterial dissections observed during angioplasty procedures. We also compared morbidity (modified Rankin Scale score of 3-5) and mortality outcomes among patients stratified by the initial balloon used, either compliant (n = 10) or noncompliant (n = 20) balloons. Results demonstrated no significant difference in the proportion of patients who died during hospitalization (3 of 10 vs 4 of 20; P = .89) and those discharged with disability (6 of 10 vs 5 of 20; P = .07).
All arterial segments that underwent balloon angioplasty were individually reviewed to determine the degree of vasospasm before and after the first-time angioplasty (Table 4) . Compliant balloons were more likely to achieve a normal or supranormal vessel diameter compared with noncompliant balloons (81% vs 53%; P = .01). Independent of the type of balloon used, there was a significantly lower rate of the need for repeat angioplasty (P = .01) when the first-time angioplasty resulted in a normal or supranormal diameter (n = 54) compared with subnormal (mild or moderate) results (n = 31).
DISCUSSION
The results of the current study failed to demonstrate any differential results based on the characteristics of the balloon used. The current existing balloons include compliant balloons that are available in limited diameters and lengths. These are primarily manufactured by a single company (ev3 Inc.) and have favorable properties that are attractive for use in the treatment of cerebral vasospasm. The degree of compliance allows the balloon to take the ''shape'' of the vessel and exert a uniform dilation. The balloon is also highly navigable because of the presence of a single lumen intended for the use with a microwire, but access into sharp vessel origins (ie, anterior cerebral artery) requires proper wire shaping and careful navigation to preserve the wire shape. In contrast, the high compliance of these balloons allows the nominal diameter of the inflated balloon to be determined by volume without any clear relationship to pressure transduced leading to poorly quantified radial force exertion during inflation, increasing the risk of rupturing the arterial segment. The resistance to radial expansion of the balloon inflation is transmitted through the fluid coupled circuit and perceived by manual touch at the plunger of the syringe with concurrent assessment of balloon expansion pattern under fluoroscopic visualization. Because of the large component of subjective assessment dictating the balloon inflation, there is substantial variation in performance of the angioplasty procedure. The manufacturer has developed a precision injector syringe (Cadence; ev3 Inc.), which operates by a screw thread for exact volume delivery for controlled balloon expansion. Noncompliant balloons are manufactured by various companies (Boston Scientific, Abbott Vascular, Medtronic). Because of their poor compliance property, the nominal diameter of inflation is achieved by reaching an insufflation pressure measured in atmospheres. This inflation is usually performed using a manual inflation device, resulting in a predictable and reproducible inflation diameter. Many operators prefer to use noncompliant balloons to perform angioplasty because of such benefits. However, these balloons have 2 lumens (wire and inflation), they are more difficult to navigate, and on occasion they can compromise guide catheter stability because of retropulsion observed during advancement of the balloon catheter.
Despite the different balloons used in the study, we did not observe a single case requiring emergent crossover from compliant to noncompliant balloon or vice versa during first-time or repeat angioplasty procedures because of technical difficulties or balloon navigability.
Based on our results, either balloon for dilation of vasospastic arteries is an acceptable option for the treatment of SAH-related vasospasm refractory to medical therapy. At our institution, operators are targeting a normal posttreatment caliber rather than any improvement in caliber, and if needed, they are more inclined to perform a second angioplasty using a larger balloon if the response of the first angioplasty was suboptimal. The costeffectiveness is an important component because of the increased cost of the equipment, but that has not been used by operators at our institution in the decision-making process. This issue is expected to gain more importance because Medicare continues to consider intracranial angioplasty for cerebral vasospasm experimental/investigational and thus not meeting the criteria for reimbursement.
The overall rate of 20% angiographic recurrence rate reported in our study for therapeutic angioplasty after a previous angioplasty is within range of the 12% to 26% 11, 25 reported in the literature. In vessels where the original (normal) or larger than normal (supranormal) diameter was achieved after the first-time angioplasty, there was a significant reduction in the need for repeat angioplasty treatment. This finding was independent of the type of balloon used. Therefore, achieving an absolute normal or supranormal original vessel diameter during the first procedure may prevent the need for a future angioplasty. This statistical difference in the reduction for repeat angioplasty treatment when a normal or supranormal diameter is obtained should be interpreted with the understanding that the results may overrepresent the risk or benefit because of the small sample size in various strata.
We acknowledge that the principal weakness of our study is the retrospective design, allowing the results to be confounded by operator bias (choice of balloon according to operator). We decided not to emphasize comparative clinical outcomes because of the small sample size and presence of several confounders that affect clinical outcome. Our goal was to determine whether the characteristics of balloons used for the initial therapeutic angioplasty result in differential rates of vasospasm recurrence and the need for a second treatment with subsequent reduction in cerebral infarctions in the affected arterial distribution. In addition to angioplasty, all patients included in the study underwent superselective intra-arterial vasodilator infusion as part of the procedure to treat vessels not amenable to angioplasty (see Patients and Methods), thus precluding a comparison between angioplasty procedures with or without adjunctive vasodilator treatment.
We considered a reduction of vasospasm recurrence after angioplasty to be an adequate marker for a successful angioplasty. The absence of symptomatic recurrent vasospasm rather than any recurrent vasospasm is a better surrogate marker for successful procedures defined by clinical outcomes. Although vasospasm recurrence may be associated with ischemic symptoms, detection of recurrence may depend on the frequency of follow-up angiography and ability to detect neurological deterioration. The effect of angioplasty (with or without recurrence) on clinical outcomes is also a modest effect because additional factors such as age, initial Hunt and Hess grade, time interval between symptomatic vasospasm onset and treatment, and distal vasospasm also contribute to clinical outcomes. [26] [27] [28] [29] However, avoiding a repeat angioplasty does decrease the risk of iatrogenic stroke and arterial dissection or rupture and potentially reduces radiation exposure and risk of contrast-induced nephropathy.
CONCLUSION
The characteristics of balloons used for the initial therapeutic angioplasty did not result in differential rates of vasospasm recurrence and need for a second treatment. Both compliant and noncompliant balloons can be safely used for therapeutic angioplasty in cerebral vasospasm in selected patients after SAH. Obtaining a normal or supranormal immediate postangioplasty result was associated with a significant reduction in the need for future therapeutic angioplasties.
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